General Anesthetics in CAncer REsection Surgery (GA-CARES) Trial

Conditions

Anesthesia, General, Surgical Oncology

Brief summary

This is a large pragmatic multicenter trial comparing maintenance of general anesthesia with total intravenous anesthesia using propofol versus volatile agent (sevoflurane, isoflurane, or desflurane) during cancer surgery. The primary endpoint is all-cause mortality.

E. Guerrero, Jamie L. Romeiser, Samuel DeMaria, Jacob W. Nadler, Timothy D. Quinn et al. (9 authors)

Journal of Clinical Oncology2025-06-04

10.1200/jco.2025.43.17_suppl.lba1512

Recurrence-free survival after curative resection of non-small cell lung cancer between inhalational gas anesthesia and propofol-based total intravenous anesthesia: a multicenter, randomized, clinical trial (GAS TIVA trial): protocol description.

Kim J, Yoon S, Song IK, Lee K, Hwang W, Kim H, Lee DK, Lim HK, Kim SH, Lee JW, Hong B, Blank RS, Pedoto A, Popescu W, Theresa G, Martin AK, Patteril M, Pathanasethpong A, Thongsuk Y, Pisitpitayasaree T, Huang A, Yu H, Kapoor PM, Kim K, Chi SA, Ahn HJ.

2024-07-233 citations

10.1186/s13741-024-00436-1

General Anesthetics in CAncer REsection Surgery (GA-CARES) randomized multicenter trial of propofol vs volatile inhalational anesthesia: protocol description.

Bennett-Guerrero E, Romeiser JL, DeMaria S, Nadler JW, Quinn TD, Ponnappan SK, Yang J, Sasson AR.

2023-01-113 citations

10.1186/s13741-022-00290-z

Interventions

DRUGPropofol

Maintenance of general anesthesia with propofol infusion

DRUGVolatile Agent

Maintenance of general anesthesia with volatile agent (sevoflurane, desflurane, or isoflurane)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Patients with known or suspected cancer and scheduled to undergo any of the following oncologic surgical procedures: * Lobectomy or pneumonectomy * Esophagectomy * Radical (total) cystectomy * Pancreatectomy * Partial hepatectomy * Hyperthermic intraperitoneal chemotherapy (HIPEC) * Gastrectomy (subtotal or total) * Cholecystectomy or bile duct resection

Exclusion criteria

* Age less than 18 years * American Society of Anesthesiologist Class 5 * Projected life expectancy less than 30 days * Known or suspected hypersensitivity to either propofol, e.g. egg or soy allergy, or volatile general anesthetic agents * Known or suspected history of malignant hyperthermia

Design outcomes

Primary

Measure	Time frame	Description
All-cause mortality	2 year minimum	Time to event

Secondary

Measure	Time frame	Description
Recurrence free survival	Minimum 2 years	Time to event
All-cause mortality as a binary outcome	2 years	—

Countries

United States

Outcome results

None listed